Award Winning Actor And Hip-Hop Artist Common Joins Allergan's See America(SM) Initiative To Further The Fight Against Preventable Blindness

The video harnesses Common's striking spoken word ability, calling on Americans to fight against vision loss and prioritize their vision. Common highlights the 61 million Americans at-risk of severe vision loss¹, and challenges us all to imagine a life without sight.

"I'm proud to join Allergan in the fight against preventable blindness," said Common. "Sight is something that far too many of us take for granted. I hope our message resonates with people across the country, no matter what age or background."

Common's involvement echoes the mission of Allergan's See America initiative by raising awareness to make sure that each and every one of us makes the time to prioritize our vision. Taking steps as simple as regular comprehensive eye exams can help detect eye diseases like glaucoma, diabetic retinopathy or age-related macular degeneration early, before irreversible damage is done.²

On Common's partnership with See America, "We are excited to have joined forces with Common to raise awareness of the important issue of preventable blindness in America. This video marks the first of many ways in which we aim to educate and engage the public. Common shares our bold approach to life, and we believe that this video will take us one step closer to nationwide appreciation for the gift of sight," said Herm Cukier, Allergan Senior Vice President of Eye Care.

To watch the video, and to learn more about See America, visit www.SeeAmerica.vision.

ABOUT SEE AMERICA:
Allergan, a global leader in eye care for nearly 70 years, has recently launched See America to fight against preventable blindness and vision impairment in America. See America has set out to make vision health a priority across the U.S., increase awareness of diseases that cause preventable blindness, and bring critical access to vision care to those who need it most. To find out more about See America, visit www.SeeAmerica.vision

ABOUT ALLERGAN PLC.
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care.  This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life.  Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com

Allergan Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

¹ CDC_Keep an Eye on Your Vision Health 
² CDC_Keep an Eye on Your Vision Health

CONTACTS:
Media:
Mark Marmur
[email protected]
+1 (862) 261 7558

Suzanne Jacobson
[email protected]
+1 (201) 427 8879

Karina Calzadilla
[email protected]
+1 (862) 261 7328

SOURCE Allergan